180 Wealth Advisors LLC Sells 2,339 Shares of Bristol Myers Squibb Company $BMY

180 Wealth Advisors LLC reduced its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 12.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 16,015 shares of the biopharmaceutical company’s stock after selling 2,339 shares during the period. 180 Wealth Advisors LLC’s holdings in Bristol Myers Squibb were worth $741,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the business. FSM Wealth Advisors LLC increased its position in Bristol Myers Squibb by 85.8% in the 2nd quarter. FSM Wealth Advisors LLC now owns 12,770 shares of the biopharmaceutical company’s stock worth $594,000 after buying an additional 5,897 shares during the period. OLD Point Trust & Financial Services N A increased its position in Bristol Myers Squibb by 9.7% in the 2nd quarter. OLD Point Trust & Financial Services N A now owns 16,301 shares of the biopharmaceutical company’s stock worth $755,000 after buying an additional 1,440 shares during the period. Caliber Wealth Management LLC KS increased its position in Bristol Myers Squibb by 95.7% in the 2nd quarter. Caliber Wealth Management LLC KS now owns 7,257 shares of the biopharmaceutical company’s stock worth $336,000 after buying an additional 3,549 shares during the period. Rehmann Capital Advisory Group increased its position in Bristol Myers Squibb by 6.9% in the 2nd quarter. Rehmann Capital Advisory Group now owns 36,700 shares of the biopharmaceutical company’s stock worth $1,699,000 after buying an additional 2,372 shares during the period. Finally, Parcion Private Wealth LLC increased its position in Bristol Myers Squibb by 5.8% in the 2nd quarter. Parcion Private Wealth LLC now owns 6,303 shares of the biopharmaceutical company’s stock worth $292,000 after buying an additional 345 shares during the period. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb Price Performance

Shares of BMY stock opened at $43.84 on Friday. The stock’s fifty day simple moving average is $45.75 and its 200 day simple moving average is $47.14. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11. The firm has a market cap of $89.24 billion, a price-to-earnings ratio of 17.68, a P/E/G ratio of 2.29 and a beta of 0.33. Bristol Myers Squibb Company has a one year low of $42.96 and a one year high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, beating the consensus estimate of $1.07 by $0.39. The business had revenue of $12.27 billion for the quarter, compared to analyst estimates of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.Bristol Myers Squibb’s quarterly revenue was up .6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.07 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. On average, analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd will be paid a $0.62 dividend. The ex-dividend date of this dividend is Friday, October 3rd. This represents a $2.48 dividend on an annualized basis and a yield of 5.7%. Bristol Myers Squibb’s payout ratio is currently 100.00%.

Analyst Ratings Changes

Several brokerages have recently weighed in on BMY. Weiss Ratings reissued a “hold (c-)” rating on shares of Bristol Myers Squibb in a report on Tuesday, October 14th. Daiwa America lowered Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 5th. Morgan Stanley reissued a “hold” rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. Citigroup reissued a “neutral” rating on shares of Bristol Myers Squibb in a report on Monday, October 13th. Finally, Daiwa Capital Markets lowered Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price objective on the stock. in a report on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and fourteen have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $57.23.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the business’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the transaction, the executive vice president owned 167,379 shares of the company’s stock, valued at approximately $7,922,048.07. The trade was a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.09% of the company’s stock.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.